SCHEMBL4019893

SCHEMBL4019893

COC(=O)C=Cc1ccc([N+](=O)[O-])cc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 5/20 0.50
MAPK1 P28482 4/20 0.50
MEN1 O00255 4/20 0.50
HPGD P15428 3/20 0.50
PTGS2 P35354 1/20 0.50
HSP90AA1 P07900 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NLRP1 Q9C000 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
HTT P42858 1/20 0.49
POLB P06746 3/20 0.46
TP53 P04637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11938125 1.00 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL5509505 0.86 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL13145899 0.86 ALDH1A1 (0.60) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL3919839 0.86 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL7204425 0.86 PTGS2 (0.50) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL14384259 0.86 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL3928524 0.86 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL5509506 0.86 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL7204421 0.86 PTGS2 (0.50) ALDH1A1KMT2AMAPTMAPK1MEN1
SCHEMBL1013073 0.85 STAT3 (0.53) ALDH1A1KMT2AMAPTMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227469-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2012-07-24 US disclosed
US-20090197879-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS BALAN CHENERA 2009-08-06 US disclosed
US-7534798-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-05-19 US disclosed
EP-1745034-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2007-01-24 EP disclosed
WO-2005077938-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-08-25 WO disclosed
US-20050182067-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197879-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 ALDH1A1 3238/4885KMT2A 3777/4885MAPT 755/4885
US-20050182067-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3238/4885KMT2A 3777/4885MAPT 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.